Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2

NCT00004883 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

84

Enrollment

NIH

Sponsor class

Conditions

Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: trastuzumab
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)